JPRN-UMIN000039529
Recruiting
未知
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer- - All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ROS1 fusion gene-positive unresectable advanced or metastatic non-small cell lung cancer
- Sponsor
- Chugai Pharmaceutical Co. Ltd.
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
All-Patient General Drug Use Surveillance of Rozlytrek Capsule - Advanced or recurrent solid tumors with NTRK gene fusionsAdvanced or recurrent solid tumors with NTRK gene fusionsJPRN-UMIN000037833Chugai Pharmaceutical Co. Ltd.200
Recruiting
Not Applicable
All-Patient General Drug Use Surveillance of Rozlytrek Capsule -ROS1 fusion gene-positive unresectable advanced or recurrent non-small cell lung cancerJPRN-UMIN000046619Chugai Pharmaceutical Co. Ltd.200
Recruiting
Not Applicable
General Drug Use Surveillance (All Patient Surveillance) of ENSPRYNG Syringes for Subcutaneous Injection - Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)JPRN-UMIN000041047Chugai Pharmaceutical Co. Ltd.330
Recruiting
Not Applicable
General Drug Use Surveillance of RONAPREVE injection set (casirivimab [genetical recombination] and imdevimab [genetical recombination])- SARS-CoV-2 infection or prevention of onsetJPRN-UMIN000044927Chugai Pharmaceutical Co. Ltd.770
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100